SMMTSummit TherapeuticsRunning, no new patients
Phase III Study of AK112 for NSCLC Patients
Non-Squamous Non-small Cell Lung Cancer
10Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +10
Main results were due Apr 2025, none posted yet
Counts until it's fixed
Worry score10
Score over time
- Stage
- Phase 3
- Patients
- 420 (final count)
- Started
- May 4, 2023
- Main results expected
- Apr 12, 2025
- Fully finished
- Dec 31, 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-free survival (PFS)
Measured over: Up to 2 years
Overall Survival (OS) in the ITT population
Measured over: Up to 2 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- results_overdue: base 10, now 10, since 2025-04-12, no fading
Raw record changes
- none yet
Trial ID NCT06396065 · record last updated 2026-07-28 · checked 2026-11-09 15:47 UTC